摘要
目的为肿瘤患者安全使用贝伐珠单抗提供参考。方法回顾分析1例65岁肺腺癌女性患者使用贝伐珠单抗治疗致糖尿病酮症酸中毒(DKA)的诊疗经过,结合文献复习分析其可能的发生机制和原因。结果与结论分析患者诊疗经过,排除其他药物和疾病因素导致的DKA;依据诺氏药物不良反应评估量表,考虑DKA为使用贝伐珠单抗所致,予血液透析治疗1次后患者酸中毒迅速改善。贝伐珠单抗致DKA属临床罕见不良反应,临床医师需意识到贝伐珠单抗可能影响胰腺功能,诱发DKA,应做到早期发现和处理,从而改善患者预后。
OBJECTIVE To provide reference for the safe use of bevacizumab in cancer patients.METHODS The diagnosis and treatment of a 65-year-old female lung adenocarcinoma patient with diabetic ketoacidosis(DKA)induced by bevacizumab was retrospectively analyzed,and the possible mechanisms and causes were analyzed based on literature review.RESULTS&CONCLUSIONS The diagnosis and treatment process of patients were analyzed,and DKA caused by other drugs and disease factors were excluded.DKA was considered to be caused by the use of bevacizumab according to Naranjo’s ADR evaluation scale;the acidosis of the patient improved rapidly after one hemodialysis treatment.DKA caused by bevacizumab is rare in clinic,clinicians should be aware that bevacizumab may affect pancreatic function and induce DKA,and early detection and treatment should be achieved to improve the prognosis.
作者
徐保平
彭怀文
喻怀斌
沈男逊
王晓涛
XU Baoping;PENG Huaiwen;YU Huaibin;SHEN Nanxun;WANG Xiaotao(Dept.of ICU,the Fourth Clinical Medical College of Anhui University of Chinese Medicine(Lu’an Hospital of Traditional Chinese Medicine),Anhui Lu’an 237000,China;Dept.of Pharmacy,the Fourth Clinical Medical College of Anhui University of Chinese Medicine(Lu’an Hospital of Traditional Chinese Medicine),Anhui Lu’an 237000,China;Dept.of Traditional Chinese Medicine,Ehu Branch of Xishan People’s Hospital of Wuxi City,Jiangsu Wuxi 214116,China)
出处
《中国药房》
CAS
北大核心
2024年第7期877-880,共4页
China Pharmacy
基金
安徽中医药大学临床科研项目(六安市中医院专项)(No.2021LAYB005,No.2021LAQN010)。
